Reverse transcription of the HIV‐1 pandemic

  title={Reverse transcription of the HIV‐1 pandemic},
  author={Aravind Basavapathruni and Karen S. Anderson},
  journal={The FASEB Journal},
  pages={3795 - 3808}
The HIV/AIDS pandemic has existed for >25 years. Extensive work globally has provided avenues to combat viral infection, but the disease continues to rage on in the human population and infected ~4 million people in 2006 alone. In this review, we provide a brief history of HIV/AIDS, followed by analysis of one therapeutic target of HIV‐1: its reverse transcriptase (RT). We discuss the biochemical characterization of RT in order to place emphasis on possible avenues of inhibition, which now… 
Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review Article
The development of effective anti-HIV drugs is difficult due to wide Review Article Behja and Jemal; IRJPAC, 20(3): 1-16, 2019; Article no.52536 2 variations in nucleotide and amino acid sequences.
HIV-1 and HIV-2 Reverse Transcriptases: Different Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors
Experiments show that while HIV-1 RT can adopt either an exclusion- or excision-based resistance mechanism against AZT, HIV-2 RT can use only the exclusion mechanism.
Dendrimers in Anti-HIV Therapy
Dendrimers, a new class of polymeric molecules, are potential candidates for developing preventive antiretroviral vaccines where the delivery vehicles have low level cytotoxicity and targeted action.
Investigation of the C-Terminal Helix of HIV-1 Matrix: A Region Essential for Multiple Functions in the Viral Life Cycle: A Dissertation
This thesis sought to examine whether a highly conserved glutamate residue at position 99 in the understudied C-terminal helix of MA is required for HIV-1 replication, and found that substitution of this glutamate with either a valine or lysine residue disrupted Env incorporation into nascent HIV particles, and abrogated their ability to fuse with target-cell membranes.
Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.
The available data warrant further investigation on the impact of C-terminal mutations in combination with classic resistance-associated mutations, on changes in viral load, and response to treatment with different classes of reverse transcriptase inhibitors.
Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Structural-based optimization of diaryl ether inhibitors led to the discovery of a new series of pyrazolo[3,4-c]pyridazine NNRTIs that bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded volume relative to most other inhibitors in this class.
Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase*
It is demonstrated that V75I is also selected under the selective pressure of a monophosphorylated prodrug that was designed to bypass the bottleneck in drug activation to the triphosphate form (ACV-TP).
Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
RT is introduced and major advances from experimental and computational biophysical experiments toward an understanding of RT function and the inhibitory mechanism(s) of NNRTIs are highlighted.
Thymidine Analogue Resistance Suppression by V75I of HIV-1 Reverse Transcriptase
Interestingly, in the sequence context of an excision-proficient RT, the introduction of V75I led to a significant decrease of its ATP-dependent excision activity on AZT-, d4T-, and acyclovir-terminated primers, which was further demonstrated in phenotypic assays.


TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.
TSAO derivatives are a peculiar group of highly functionalized nucleosides that belong to the so-called nonnucleoside RT inhibitors (NNRTIs), which exert their unique selectivity for HIV-1 through a specific interaction with the p51 subunit of HIV- 1 RT.
Molecular targets for AIDS therapy.
In the future, non-nucleoside-type drugs will likely become more important in the experimental therapy of AIDS, and antiretroviral therapy will exert major effects against the morbidity and mortality caused by HIV.
Basics of the virology of HIV-1 and its replication.
  • S. Sierra, B. Kupfer, R. Kaiser
  • Biology
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2005
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
This work describes the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells, and the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes.
Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention.
Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
  • J. Balzarini
  • Biology, Chemistry
    Current topics in medicinal chemistry
  • 2004
Almost fifteen years ago, the first non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI) lead compounds have been discovered and have proven beneficial when included in drug combination (triple or quadruple) therapy, preferably in the presence of protease inhibitors and NRTIs.
Fidelity of HIV-1 reverse transcriptase.
The high error rate of HIV-1 reverse transcriptase in vitro translates to approximately five to ten errors per HIV- 1 genome per round of replication in vivo, which suggests that misincorporation by AIDS virus is, at least in part, responsible for the hypermutability of the AIDS virus.
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
Dipyridodiazepinones inhibition of HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes.
Site-specific mutagenesis of AIDS virus reverse transcriptase
This study has used site-directed mutagenesis of this enzyme expressed in Escherichia coli to reveal several important functional regions of the protein including putative components of the triphosphate binding site and pyrophosphate exchange sites.
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
HIV-1 variants resistant to nevirapine emerged with passage in cell culture in the presence of drug and was stable with continued passage in the absence of drug, while mutants were also resistant to a tetrahydroimidazo and retained their sensitivity to the other reverse transcriptase inhibitors.